Aisling Capital Management LP Elevation Oncology, Inc. Transaction History
Aisling Capital Management LP
- $273 Million
- Q4 2024
A detailed history of Aisling Capital Management LP transactions in Elevation Oncology, Inc. stock. As of the latest transaction made, Aisling Capital Management LP holds 2,834,910 shares of ELEV stock, worth $992,218. This represents 0.6% of its overall portfolio holdings.
Number of Shares
2,834,910
Previous 2,834,910
-0.0%
Holding current value
$992,218
Previous $1.7 Million
3.29%
% of portfolio
0.6%
Previous 0.7%
Shares
1 transactions
Others Institutions Holding ELEV
# of Institutions
70Shares Held
39.3MCall Options Held
100Put Options Held
3.3K-
Frazier Life Sciences Management, L.P. Menlo Park, CA5.99MShares$2.1 Million0.21% of portfolio
-
Tang Capital Management LLC San Diego, CA4.76MShares$1.67 Million0.21% of portfolio
-
Farallon Capital Management LLC San Francisco, CA3.53MShares$1.23 Million0.01% of portfolio
-
Bvf Inc San Francisco, CA2.97MShares$1.04 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.61MShares$913,5150.0% of portfolio
About Elevation Oncology, Inc.
- Ticker ELEV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 23,300,900
- Market Cap $8.16M
- Description
- Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced sol...